1-4 of 4
Yuka Miyamae
Close
Sort by
Journal Articles

Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase

Yoko Tabe, MD PhD, Masako Harada, PhD, Yuka Miyamae, Tsutomu Fujimura, Saiko Kazuno, Takashi Ueno, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3626.
https://doi.org/10.1182/blood.V124.21.3626.3626
Published: 2014
Journal Articles

The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis / Gluconeogenesis, Enhancing Antitumor Effects in Mantle Cell Lymphoma

Yoko Tabe, MD PhD, Masako Harada, PhD, Yuka Miyamae, Hiromichi Matsushita, MD PhD, Kensuke Kojima, MD PhD, Tsutomu Fujimura, Saiko Kazuno, Takashi Ueno, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2014) 124 (21): 925.
https://doi.org/10.1182/blood.V124.21.925.925
Published: 2014
Journal Articles

Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells

Yoko Tabe, MD PhD, Masako Harada, PhD, Yuka Miyamae, Kaoru Mogushi, Saiko Kazuno, Tsutomu Fujimura, Hiromichi Matsushita, MD PhD, Takashi Ueno, Takehiko Yokomizo, MD PhD, Takashi Miida, MD PhD, Ismael Samudio, PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1013.
https://doi.org/10.1182/blood.V124.21.1013.1013
Published: 2014
Journal Articles

Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma

Yoko Tabe, MD PhD, Masako Harada, PhD, Yuka Miyamae, Saiko Kazuno, Tsutomu Fujimura, Takashi Ueno, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2254.
https://doi.org/10.1182/blood.V124.21.2254.2254
Published: 2014